SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the WPP class action lawsuit seeks to represent purchasers or acquirers of WPP plc (NYSE: WPP) common stock between February 27, 2025 and July 8, 2025, both dates inclusive (the “Class Period”). Captioned Marty v. WPP plc, No. 25-cv-08365 (S.D.N.Y.), the WPP class action lawsuit charges WPP and certain of WPP’s top executives with violations of the Securities Exchange Act of 1934. If you suffered sub ...

, /PRNewswire/ -- The Ademi Firm is investigating Akero (NASDAQ: AKRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Akero will receive $54.00 per share, representing an equity value of approximately $4.7 billion. Shareholders will also receive a c ...

, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Charter Communications, Inc. (NASDAQ: CHTR) securities, including purchasers of call options or sellers of put options between July 26, 2024 and July 24, 2025, all dates inclusive (the "Class Period"), have until Tuesday, October 14, 2025 to seek appointment as lead plaintiff of the Charter Communications class action lawsuit. Captioned Sandoval v. Charter Communications, Inc., No. 25-cv-06747 (S.D ...

, /PRNewswire/ -- The Ademi Firm is investigating Comerica (NYSE: CMA) for possible breaches of fiduciary duty and other violations of law in its transaction with Fifth Third. 270k+ Journalists Opted In Ademi & Fruchter LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 SOURCE Ademi LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets Click here to learn how to join our investigation and obtain additional information or contact us at [e ...

Ademi & Fruchter LLP Guri Ademi Toll Free: (866) 264-3995 Fax: (414) 482-8001 , /PRNewswire/ -- The Ademi Firm is investigating Heidrick (NASDAQ: HSII) for possible breaches of fiduciary duty and other violations of law in its transaction with Advent and Corvex. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of Heidrick will receive $59.00 per share in an ...

Core Viewpoint - The article discusses a class action lawsuit against Charter Communications, alleging violations of the Securities Exchange Act of 1934 due to misleading statements and failure to disclose significant impacts on the company's performance related to the end of the Federal Communications Commission's Affordable Connectivity Program [1][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Sandoval v. Charter Communications, Inc., and it involves purchasers or acquirers of Charter Communications securities from July 26, 2024, to July 24, 2025 [1]. - Investors have until October 14, 2025, to seek appointment as lead plaintiff in the lawsuit [2][6]. - The lawsuit alleges that Charter Communications and its executives made false statements regarding the company's ability to manage the impact of the Affordable Connectivity Program's end, which affected customer retention and revenue [4]. Group 2: Financial Impact - On July 25, 2025, Charter Communications reported second quarter 2025 financial results, showing EBITDA of $5.7 billion, indicating a growth of 0.5% [5]. - The company experienced a decline of 117,000 Internet customers, with approximately 50,000 disconnects attributed to the end of the Affordable Connectivity Program [5]. - Following the financial results announcement, Charter Communications' stock price fell by more than 18% [5]. Group 3: Company Background - Charter Communications operates as a broadband connectivity and cable operator, serving both residential and commercial customers [3]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the investors, is recognized for its significant recoveries in securities fraud cases, having recovered over $2.5 billion for investors in 2024 alone [7].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Hims & Hers Health, Inc. related to misleading statements and actions that may have jeopardized shareholder interests [1]. Group 1: Allegations Against Hims & Hers Health, Inc. - Insiders at Hims & Hers Health allegedly misrepresented or failed to disclose involvement in the deceptive promotion and sale of illegitimate versions of Wegovy, which posed risks to patient safety [1]. - There is a substantial risk that the company's collaboration with Novo Nordisk could be terminated due to these actions [1]. - Positive statements regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis [1].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Sarepta Therapeutics, Inc. related to the misrepresentation of safety risks associated with the ELEVIDYS treatment [1] Group 1: Allegations Against Sarepta Therapeutics - Insiders at Sarepta Therapeutics allegedly caused the company to misrepresent or fail to disclose significant safety risks posed by the ELEVIDYS treatment [1] - The trial regimes and protocols for ELEVIDYS reportedly failed to detect severe side effects, leading to concerns about patient safety [1] - The severity of adverse events from ELEVIDYS treatment may result in the company halting recruitment and dosing in trials, attracting regulatory scrutiny, and increasing risks around the therapy's approvals [1] - Insiders are accused of materially misleading stakeholders and lacking a reasonable basis for their positive statements regarding ELEVIDYS [1]

Core Insights - The Ademi Firm is investigating Semler Scientific for potential breaches of fiduciary duty and other legal violations related to its transaction with Strive [1][3] - Shareholders of Semler Scientific will receive 21.05 Class A common shares of Strive, valued at approximately $90.52 per share based on trading prices as of September 19, 2025 [2] - The transaction agreement restricts competing offers for Semler Scientific by imposing significant penalties for accepting alternative bids, raising concerns about the board's fiduciary responsibilities [3]

Core Points - Metsera (Nasdaq: MTSR) is involved in a transaction with Pfizer, where shareholders will receive $47.50 per share, resulting in an enterprise value of approximately $4.9 billion [2][3] - The transaction agreement includes provisions that significantly limit competing offers for Metsera, imposing penalties if a competing bid is accepted [3] Investigation Details - The Ademi Firm is investigating potential breaches of fiduciary duty by Metsera's board of directors regarding their responsibilities to shareholders in light of the transaction with Pfizer [1][3] - The investigation focuses on whether the board is acting in the best interests of all shareholders, given the substantial benefits insiders will receive from change of control arrangements [2][3]